Freeline Therapeutics Holdings plc
| NASDAQ: FRLN | Healthcare / Biotechnology / United Kingdom |
| 6.36 | -0.0400 | -0.62% | Vol 82.25K | 1Y Perf 995.89% |
| Dec 6th, 2023 16:00 DELAYED |
| BID | 6.25 | ASK | 6.44 | ||
| Open | 6.35 | Previous Close | 6.40 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 6.25 | Analyst Rating | Hold 3.00 | |
| Potential % | -1.73 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 52.53 | Earnings Rating | — | |
| Market Cap | 27.61M | Earnings Date | 21st Nov 2023 | |
| Alpha | -0.07 | Standard Deviation | 0.19 | |
| Beta | 0.64 |
Today's Price Range 6.256.40 | 52W Range 2.1110.20 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.79% | ||
| 1 Month | 11.19% | ||
| 3 Months | 93.31% | ||
| 6 Months | 166.67% | ||
| 1 Year | 995.89% | ||
| 3 Years | -63.62% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -101.68 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -82.27 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -82.08 | |||
Return on invested Capital Q | -13.24 | |||
Return on invested Capital Y | -75.84 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.20 | ||||
| 0.46 | ||||
| - | ||||
| - | ||||
| -0.50 | ||||
| -1.46 | ||||
| 0.46 | ||||
| 1.06 | ||||
| -21 765 400.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.10 | ||||
| 3.30 | ||||
| 0.12 | ||||
| 0.17 | ||||
| - | ||||
| Leverage Ratio | 1.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.24 | -0.18 | 25.00 |
| Q02 2023 | -3.62 | -0.21 | 94.20 |
| Q01 2023 | -1.64 | -0.29 | 82.32 |
| Q04 2022 | - | -5.22 | - |
| Q03 2022 | -6.42 | -2.99 | 53.43 |
| Q02 2022 | -8.06 | -4.78 | 40.69 |
| Q01 2022 | -8.66 | -9.40 | -8.55 |
| Q04 2021 | -10.75 | -14.48 | -34.70 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.20 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 82.25K |
| Shares Outstanding | 4.34K |
| Shares Float | 11.67M |
| Trades Count | 340 |
| Dollar Volume | 519.37K |
| Avg. Volume | 123.87K |
| Avg. Weekly Volume | 70.80K |
| Avg. Monthly Volume | 80.86K |
| Avg. Quarterly Volume | 219.94K |
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) stock closed at 6.36 per share at the end of the most recent trading day (a -0.62% change compared to the prior day closing price) with a volume of 82.25K shares and market capitalization of 27.60M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 236 people. Freeline Therapeutics Holdings plc CEO is Theresa Heggie.
The one-year performance of Freeline Therapeutics Holdings plc stock is 995.89%, while year-to-date (YTD) performance is 1238.67%. FRLN stock has a five-year performance of %. Its 52-week range is between 2.11 and 10.2, which gives FRLN stock a 52-week price range ratio of 52.53%
Freeline Therapeutics Holdings plc currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.46, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -82.27%, a ROC of -82.08% and a ROE of -101.68%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Freeline Therapeutics Holdings plc, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. Freeline Therapeutics Holdings plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Freeline Therapeutics Holdings plc is Hold (3), with a target price of $6.25, which is -1.73% compared to the current price. The earnings rating for Freeline Therapeutics Holdings plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Freeline Therapeutics Holdings plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Freeline Therapeutics Holdings plc has a Buy technical analysis rating based on Technical Indicators (ADX : 50.76, ATR14 : 0.54, CCI20 : 76.42, Chaikin Money Flow : -0.20, MACD : 0.42, Money Flow Index : 70.46, ROC : 35.88, RSI : 62.22, STOCH (14,3) : 93.33, STOCH RSI : 0.71, UO : 53.97, Williams %R : -6.67), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Freeline Therapeutics Holdings plc in the last 12-months were:
Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings PLC is a clinical stage, systemic AAV-based gene therapy company. The company is developing therapies for Haemophilia B, Fabry disease, Gaucher disease, and other diseases.
CEO: Theresa Heggie
Telephone: +44 1438906870
Address: Gunnels Wood Road, Stevenage SG1 2FX, Hertfordshire, GB
Number of employees: 236
TipRanks News for FRLN
Thu, 05 Oct 2023 12:36 GMT Promising Gaucher Disease Trial Results and Potential Parkinsons Disease Impact Bolster Analysts Buy Rating for Freeline Therapeutics Holdings
- TipRanks. All rights reserved.
